Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial ...
In this interview, Kalpana Barnes highlights how new approach methodologies are addressing the gaps in drug discovery studies ...
CNW/ - (CBV), a leading biotech accelerator, dedicated to supporting the growth of early-stage life sciences companies, is ...
Explore trends before investing – request a sample report today! In 2024, CNS gene therapy development surged, supported by ...
The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...
The 2025 Research Innovation Grants are supporting projects focused on biomarkers, risk factors, and treatments for ALS.
Inside the cell reside many tiny assembly factories and warehouses that gather together all of the proteins and RNAs—which ...
An announcement from Tiziana Life Sciences ( ($TLSA) ) is now available. On November 25, 2025, Tiziana Life Sciences announced that its Phase 2 ...
The ALS Network, in partnership with 12 ALS United member organizations, announces the selection of its 2025 Research Innovation Grantees—an accomplished group of scientists and clinicians whose work ...
News-Medical.Net on MSN
New imaging method reveals nanodomains inside ALS-linked protein droplets
Inside the cell reside many tiny assembly factories and warehouses that gather together all of the proteins and RNAs-which ...
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback